---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-016254"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T14:09:06.607914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q1 net loss $30.5M, cash $316M; FHD-286 mUM data expected Q2 2023

## Summary
- Net loss of $30.5M for Q1 2023, compared to $26.9M loss in Q1 2022; no product revenue.
- Cash and equivalents $316M as of March 31, 2023, providing runway into second half of 2025.
- Phase 1 dose escalation of FHD-286 in metastatic uveal melanoma continues; top-line data expected Q2 2023.
- FDA clinical hold on FHD-286 in AML/MDS; regulatory update expected Q2 2023.
- Collaboration revenue $5.3M, up from $3.9M; Loxo@Lilly collaboration progressing.

## SEC filing metadata
- accession: 0001628280-23-016254
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/0001628280-23-016254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/fhtx-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-016254
- JSON: https://secwatch.observer/filing/0001628280-23-016254.json
- Plain text: https://secwatch.observer/filing/0001628280-23-016254.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported the quarter ended March 31, 2023 results: revenue $5.3 million, net income $30.5 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $5.3 million
  - Net income: $30.5 million
  - Result: reported results
  source text: First Quarter 2023 Financial Highlights • Strong Balance Sheet and Cash Runway. As of March 31, 2023, the Company had $316.0 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025 . • Collaboration Revenues. Collaboration revenue was $5.3 million for the three months ended March 31, 2023, compared to $3.9 million for the three months ended March 31, 2022. The increase year-over-year was primarily driven by revenue recognized under the Lilly collaboration agreement. • Research and Development Expenses. Research and development expenses were $30.0 million for the three months ended March 31, 2023, compared to $24.5 million for the three months ended March 31, 2022. This increase was primarily due to costs associated with continued investment in R&D personnel and platform and early-stage research investments. • General and Administrative Expenses. General and administrative expenses were $8.6 million for the three months ende
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/0001628280-23-016254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.